Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS: A randomized placebo-controlled trial

Mohamad Irani, David Seifer, Richard V. Grazi, Nitasha Julka, Devika Bhatt, Bharati Kalgi, Sara Irani, Oded Tal, Geralyn Lambert-Messerlian, Reshef Tal

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Context: There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. VitaminD(VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis. Objective: The objective of the studywasto determine the effect ofVDsupplementationonTGF-β1 bioavailability in VD-deficient women with PCOS and assess whether changes in TGF-β1/soluble endoglin (sENG) levels correlate with an improvement in PCOS clinical manifestations. Design: This was a prospective, randomized, placebo-controlled trial. Setting: The study was conducted at an academic-affiliated medical center. Participants: Sixty-eight VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015. Interventions: Forty-five women received 50 000 IU of oral vitamin D3 and 23 women received oral placebo once weekly for 8 weeks. Main Outcomes Measures: Serum TGF-β1, sENG, lipid profile, testosterone, dehydroepiandrosterone sulfate, and insulin resistance were measured. The clinical parameters were evaluated before and 2 months after treatment. Results: The VD level significantly increased and normalized after VD supplementation (16.3 ± 0.9 [SEM] to 43.2±2.4 ng/mL; P-.01), whereas it did not significantly change after placebo. After the VD supplementation, there was a significant decrease in the following: the interval between menstrual periods (80±9to60±6d;P

Original languageEnglish (US)
Pages (from-to)4307-4314
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume100
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Polycystic Ovary Syndrome
Vitamin D
Biological Availability
Randomized Controlled Trials
Placebos
Dehydroepiandrosterone Sulfate
Cholecalciferol
Testosterone
Hormones
Insulin
Lipids
Primary Myelofibrosis
Insulin Resistance
Outcome Assessment (Health Care)
Serum
Endoglin

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS : A randomized placebo-controlled trial. / Irani, Mohamad; Seifer, David; Grazi, Richard V.; Julka, Nitasha; Bhatt, Devika; Kalgi, Bharati; Irani, Sara; Tal, Oded; Lambert-Messerlian, Geralyn; Tal, Reshef.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 100, No. 11, 01.11.2015, p. 4307-4314.

Research output: Contribution to journalArticle

Irani, M, Seifer, D, Grazi, RV, Julka, N, Bhatt, D, Kalgi, B, Irani, S, Tal, O, Lambert-Messerlian, G & Tal, R 2015, 'Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS: A randomized placebo-controlled trial', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 11, pp. 4307-4314. https://doi.org/10.1210/jc.2015-2580
Irani, Mohamad ; Seifer, David ; Grazi, Richard V. ; Julka, Nitasha ; Bhatt, Devika ; Kalgi, Bharati ; Irani, Sara ; Tal, Oded ; Lambert-Messerlian, Geralyn ; Tal, Reshef. / Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS : A randomized placebo-controlled trial. In: Journal of Clinical Endocrinology and Metabolism. 2015 ; Vol. 100, No. 11. pp. 4307-4314.
@article{24715faf54c341248690cfcfc56c3ba7,
title = "Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS: A randomized placebo-controlled trial",
abstract = "Context: There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. VitaminD(VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis. Objective: The objective of the studywasto determine the effect ofVDsupplementationonTGF-β1 bioavailability in VD-deficient women with PCOS and assess whether changes in TGF-β1/soluble endoglin (sENG) levels correlate with an improvement in PCOS clinical manifestations. Design: This was a prospective, randomized, placebo-controlled trial. Setting: The study was conducted at an academic-affiliated medical center. Participants: Sixty-eight VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015. Interventions: Forty-five women received 50 000 IU of oral vitamin D3 and 23 women received oral placebo once weekly for 8 weeks. Main Outcomes Measures: Serum TGF-β1, sENG, lipid profile, testosterone, dehydroepiandrosterone sulfate, and insulin resistance were measured. The clinical parameters were evaluated before and 2 months after treatment. Results: The VD level significantly increased and normalized after VD supplementation (16.3 ± 0.9 [SEM] to 43.2±2.4 ng/mL; P-.01), whereas it did not significantly change after placebo. After the VD supplementation, there was a significant decrease in the following: the interval between menstrual periods (80±9to60±6d;P",
author = "Mohamad Irani and David Seifer and Grazi, {Richard V.} and Nitasha Julka and Devika Bhatt and Bharati Kalgi and Sara Irani and Oded Tal and Geralyn Lambert-Messerlian and Reshef Tal",
year = "2015",
month = "11",
day = "1",
doi = "10.1210/jc.2015-2580",
language = "English (US)",
volume = "100",
pages = "4307--4314",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS

T2 - A randomized placebo-controlled trial

AU - Irani, Mohamad

AU - Seifer, David

AU - Grazi, Richard V.

AU - Julka, Nitasha

AU - Bhatt, Devika

AU - Kalgi, Bharati

AU - Irani, Sara

AU - Tal, Oded

AU - Lambert-Messerlian, Geralyn

AU - Tal, Reshef

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Context: There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. VitaminD(VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis. Objective: The objective of the studywasto determine the effect ofVDsupplementationonTGF-β1 bioavailability in VD-deficient women with PCOS and assess whether changes in TGF-β1/soluble endoglin (sENG) levels correlate with an improvement in PCOS clinical manifestations. Design: This was a prospective, randomized, placebo-controlled trial. Setting: The study was conducted at an academic-affiliated medical center. Participants: Sixty-eight VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015. Interventions: Forty-five women received 50 000 IU of oral vitamin D3 and 23 women received oral placebo once weekly for 8 weeks. Main Outcomes Measures: Serum TGF-β1, sENG, lipid profile, testosterone, dehydroepiandrosterone sulfate, and insulin resistance were measured. The clinical parameters were evaluated before and 2 months after treatment. Results: The VD level significantly increased and normalized after VD supplementation (16.3 ± 0.9 [SEM] to 43.2±2.4 ng/mL; P-.01), whereas it did not significantly change after placebo. After the VD supplementation, there was a significant decrease in the following: the interval between menstrual periods (80±9to60±6d;P

AB - Context: There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. VitaminD(VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis. Objective: The objective of the studywasto determine the effect ofVDsupplementationonTGF-β1 bioavailability in VD-deficient women with PCOS and assess whether changes in TGF-β1/soluble endoglin (sENG) levels correlate with an improvement in PCOS clinical manifestations. Design: This was a prospective, randomized, placebo-controlled trial. Setting: The study was conducted at an academic-affiliated medical center. Participants: Sixty-eight VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015. Interventions: Forty-five women received 50 000 IU of oral vitamin D3 and 23 women received oral placebo once weekly for 8 weeks. Main Outcomes Measures: Serum TGF-β1, sENG, lipid profile, testosterone, dehydroepiandrosterone sulfate, and insulin resistance were measured. The clinical parameters were evaluated before and 2 months after treatment. Results: The VD level significantly increased and normalized after VD supplementation (16.3 ± 0.9 [SEM] to 43.2±2.4 ng/mL; P-.01), whereas it did not significantly change after placebo. After the VD supplementation, there was a significant decrease in the following: the interval between menstrual periods (80±9to60±6d;P

UR - http://www.scopus.com/inward/record.url?scp=84958635267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958635267&partnerID=8YFLogxK

U2 - 10.1210/jc.2015-2580

DO - 10.1210/jc.2015-2580

M3 - Article

C2 - 26485217

AN - SCOPUS:84958635267

VL - 100

SP - 4307

EP - 4314

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -